ANDA 203854, held by Prinston Pharmaceutical. Paroxetine Hydrochloride.
As of Nov 21, 2026, ANDA 203854 (Paroxetine), held by Prinston Pharmaceutical, was first approved by FDA on Oct 31, 2014, with 3 approved supplements and 0 published complete response letters.
Paroxetine tablets are indicated in adults for the treatment of: Major depressive disorder (MDD) Obsessive compulsive disorder (OCD) Panic disorder (PD) Social anxiety disorder (SAD) Generalized anxiety disorder (GAD) Posttraumatic stress disorder (PTSD) Paroxetine tablets are a selective serotonin reuptake inhibitor (SSRI) indicated in adults for the treatment of: Major Depressive Disorder (MDD) Obsessive Compulsive Disorder (OCD) Panic Disorder (PD) Social Anxiety Disorder (SAD) Generalized Anxiety Disorder (GAD) Posttraumatic Stress Disorder (PTSD)
| Date | Submission | Status | Documents |
|---|---|---|---|
| Oct 31, 2014 | Original application | Approved | None posted |
| ParoxetineEQ 10MG BASE · tablet;oral | Paroxetine Hydrochloride | Rx |
| ParoxetineEQ 20MG BASE · tablet;oral | Paroxetine Hydrochloride | Rx |
| ParoxetineEQ 30MG BASE · tablet;oral | Paroxetine Hydrochloride | Rx |
| ParoxetineEQ 40MG BASE · tablet;oral | Paroxetine Hydrochloride | Rx |
| Jul 15, 2024 | Supplement 3Labeling · Standard review | Approved | None posted |
| Jul 15, 2024 | Supplement 4Labeling · Standard review | Approved | None posted |
| Apr 29, 2020 | Supplement 1Labeling · Standard review | Approved | None posted |
| Oct 31, 2014 | Original application | Approved | None posted |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. “What FDA's review says” is read by a model (Claude Haiku) from FDA's summary review PDF; a field is shown only if its numbers appear in the review, and each section links the review. Drugs@FDA and FDA complete response letters